Genentech, a member of Roche (RHHBY), announced that the FDA has approved Gazyva for the treatment of adult patients with active lupus nephritis who are receiving standard therapy, as well as a shorter 90-minute infusion time after the first infusion, for eligible patients. Following four initial doses in the first year, Gazyva can be administered twice yearly, offering an effective and potentially more convenient treatment option than traditional targeted therapies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Genentech announces results from IMvigor011 study
- Roche announces results from phase III evERA Breast Cancer study
- Genentech’s Phase III evERA data showed giredestrant improved PFS survival
- Genentech presents new Phase 3 data for vamikibart
- Roche reports Phase 3 data for satralizumab in SatraGO-1, SatraGO-2